Clinical Considerations for In-Development MS Treatments

Volume 4, Issue 10

Clinical Considerations for In-Development MS Treatments

In this issue:

Where’s the newer MS research leading? How has our understanding of noninflammatory progressive MS changed? How might these findings affect what happens in the clinic?

Join us as we discuss these and other questions with Dr. Michael Kornberg from the Johns Hopkins School of Medicine in this eMultipleSclerosis Review podcast.

Learning objectives:

Discuss the mechanisms and potential roles in therapy of emerging and in-development treatments, particularly for patients with noninflammatory progressive MS.
Describe the evidence surrounding novel extended-interval dosing regimens of current infusion therapies, including natalizumab and ocrelizumab.

Author:

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Guest Faculty Disclosures

Dr. Kornberg has disclosed that he has received consulting fees from OptumRx.

Unlabeled/Unapproved Uses

Dr. Kornberg has indicated that he will discuss unlabeled/unapproved uses of evobrutinib, zanubrutinib, ibudilast,opicinumab, natalizumab, ocrelizumab, rituximab, tolebrutinib, and stem cell therapies.  

Program Directors:

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Guest Faculty Disclosures:

Dr. Kornberg has disclosed that he has received consulting fees from OptumRx.

Unlabeled/Unapproved Uses:

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: August 25, 2022
Expiration date: August 24, 2024

Start Issue